Development and validation of a high-performance liquid chromatography-electrospray ionization-mass spectrometry assay for the determination of zaleplon in human plasma

Journal of Chromatographic Science

Volumn 41, Issue 1, 2003, Pages 17-21

  Feng, Fang ^a   Jiang, Juanjuan ^a   Dai, Hui ^a   Wu, Jie ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAMIDE DERIVATIVE; HYPNOTIC SEDATIVE AGENT; METHANOL; PYRIMIDINE DERIVATIVE; WATER; ZALEPLON;

ACCURACY; ANALYTIC METHOD; ARTICLE; BLOOD; CALIBRATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG DETERMINATION; ELECTRIC POTENTIAL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IONIZATION; MASS SPECTROMETRY; METHODOLOGY; NORMAL HUMAN; PLASMA; QUANTITATIVE ANALYSIS; REFERENCE VALUE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEPARATION TECHNIQUE; STANDARD; VALIDATION PROCESS;

EID: 0037260083     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/41.1.17     Document Type: Article

References (9)

1. I.P. Day, D.E. Clody, M.M. Monaghan, M.S. Abel, J.P. Dusza, and B. Beer. Pharmacology of CL 284846, a non-benzodiazepine sedative with reduced amnestic liability (abstract). Soc. Neurosci. 18: 725 (1992).
2. R. Elie, E. Ruther, I. Farr, G. Emilien, and E. Salinas. Sleep latency is shortened during four weeks of treatment with zaleplon, a novel non-benzodiazepine hypnotic. J. Clin. Psychiatry 60: 536-44 (1999).
3. J.K. Walsh, J. Fry, C.W. Erwin, M. Roth, G. Vogel, and H. Lin. Efficacy and tolerability of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia. Drug Invest. 16: 347-54 (1998).
4. D. Allen, H.V. Curran, and M. Lader. The effects of single doses of CL 284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers. Eur. J. Clin. Pharmacol. 45: 313-20 (1993).
5. P. Danjou, I. Paty, R. Fruncillo, P. Worthington, M. Unruh, W. Cevalos, and P. Martin. A comparison of the residual effects of zaleplon and zolpidem following administration five to two hours before awakening. Br. J. Clin. Pharmacol. 48: 367-74 (1999).
6. T. Rochrs, L. Merlotti, F. Zorick, and T. Roth. Sedative, memory and performance effects of hypnotics. Psychopharmacology 116:130-34 (1994).
7. M. Darwish, P.T. Martin, W.H. Cevallos, S. Tse, S. Wheeler, and S.M. Troy. Rapid disappearance of zaleplon from breast milk after oral administration to lactating women. J. Clin. Pharmacol. 39: 670-74 (1999).
8. B. Beer, J.R. Leni, W.H. Wu, D. Clody, P. Amorusi, J. Rose, T. Mant, J. Gaudreault, A. Cato, and W. Stern. A placebo-controlled evaluatuon of single, escalating doses of CL 284,846, a nonbenzodi-azepine hypnotic. J. Clin. Pharmacol. 34: 335-44 (1994).
9. M. Kleinschnitz, M. Herderich, and P. Schreier. Determination of 1,4-benzodiazepines by high-performance liquid chromatography-electrospray tandem mass spectrometry. J. Chromatogr. B 676: 61-67 (1996).